311 related articles for article (PubMed ID: 24952959)
21. The search for the palmitoylethanolamide receptor.
LoVerme J; La Rana G; Russo R; Calignano A; Piomelli D
Life Sci; 2005 Aug; 77(14):1685-98. PubMed ID: 15963531
[TBL] [Abstract][Full Text] [Related]
22. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice.
Di Paola R; Impellizzeri D; Mondello P; Velardi E; Aloisi C; Cappellani A; Esposito E; Cuzzocrea S
Shock; 2012 Oct; 38(4):356-66. PubMed ID: 22772472
[TBL] [Abstract][Full Text] [Related]
23. Macrophage-derived lipid agonists of PPAR-α as intrinsic controllers of inflammation.
Pontis S; Ribeiro A; Sasso O; Piomelli D
Crit Rev Biochem Mol Biol; 2016; 51(1):7-14. PubMed ID: 26585314
[TBL] [Abstract][Full Text] [Related]
24. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Ueda N; Tsuboi K; Uyama T
Prog Lipid Res; 2010 Oct; 49(4):299-315. PubMed ID: 20152858
[TBL] [Abstract][Full Text] [Related]
25. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Petrosino S; Ahmad A; Marcolongo G; Esposito E; Allarà M; Verde R; Cuzzocrea S; Di Marzo V
Pharmacol Res; 2015 Jan; 91():9-14. PubMed ID: 25447594
[TBL] [Abstract][Full Text] [Related]
26. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes.
Hoareau L; Buyse M; Festy F; Ravanan P; Gonthier MP; Matias I; Petrosino S; Tallet F; d'Hellencourt CL; Cesari M; Di Marzo V; Roche R
Obesity (Silver Spring); 2009 Mar; 17(3):431-8. PubMed ID: 19131941
[TBL] [Abstract][Full Text] [Related]
27. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
28. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tsuboi K; Takezaki N; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1914-25. PubMed ID: 17712833
[TBL] [Abstract][Full Text] [Related]
29. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
[TBL] [Abstract][Full Text] [Related]
30. Assay of NAAA Activity.
Tsuboi K; Ueda N
Methods Mol Biol; 2023; 2576():261-274. PubMed ID: 36152194
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate.
Tiger G; Stenström A; Fowler CJ
Biochem Pharmacol; 2000 Mar; 59(6):647-53. PubMed ID: 10677581
[TBL] [Abstract][Full Text] [Related]
32. The Nutraceutical N-Palmitoylethanolamide (PEA) Reveals Widespread Molecular Effects Unmasking New Therapeutic Targets in Murine Varicocele.
Antonuccio P; Marini HR; Micali A; Romeo C; Granese R; Retto A; Martino A; Benvenga S; Cuzzocrea S; Impellizzeri D; Di Paola R; Fusco R; Cervellione RM; Minutoli L
Nutrients; 2021 Feb; 13(3):. PubMed ID: 33668991
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
Tuo W; Leleu-Chavain N; Spencer J; Sansook S; Millet R; Chavatte P
J Med Chem; 2017 Jan; 60(1):4-46. PubMed ID: 27766867
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, Molecular Modeling and Biological Evaluation of Metabolically Stable Analogues of the Endogenous Fatty Acid Amide Palmitoylethanolamide.
D'Aloia A; Arrigoni F; Tisi R; Palmioli A; Ceriani M; Artusa V; Airoldi C; Zampella G; Costa B; Cipolla L
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260658
[TBL] [Abstract][Full Text] [Related]
35. Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity.
Petrosino S; Schiano Moriello A; Verde R; Allarà M; Imperatore R; Ligresti A; Mahmoud AM; Peritore AF; Iannotti FA; Di Marzo V
J Neuroinflammation; 2019 Dec; 16(1):274. PubMed ID: 31878942
[TBL] [Abstract][Full Text] [Related]
36. New players in the fatty acyl ethanolamide metabolism.
Rahman IA; Tsuboi K; Uyama T; Ueda N
Pharmacol Res; 2014 Aug; 86():1-10. PubMed ID: 24747663
[TBL] [Abstract][Full Text] [Related]
37. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.
Cordaro M; Impellizzeri D; Siracusa R; Gugliandolo E; Fusco R; Inferrera A; Esposito E; Di Paola R; Cuzzocrea S
Toxicol Appl Pharmacol; 2017 Aug; 329():231-240. PubMed ID: 28610993
[TBL] [Abstract][Full Text] [Related]
38. Improvement of Topical Palmitoylethanolamide Anti-Inflammatory Activity by Pegylated Prodrugs.
Tronino D; Russo R; Ostacolo C; Mazzolari A; De Caro C; Avagliano C; Laneri S; La Rana G; Sacchi A; Della Valle F; Vistoli G; Calignano A
Mol Pharm; 2015 Sep; 12(9):3369-79. PubMed ID: 26289562
[TBL] [Abstract][Full Text] [Related]
39. Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
Li Y; Zhou P; Chen H; Chen Q; Kuang X; Lu C; Ren J; Qiu Y
Pharmacol Res; 2018 Jun; 132():7-14. PubMed ID: 29572189
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylethanolamine acid amidase (NAAA) inhibitors.
Vitale R; Ottonello G; Petracca R; Bertozzi SM; Ponzano S; Armirotti A; Berteotti A; Dionisi M; Cavalli A; Piomelli D; Bandiera T; Bertozzi F
ChemMedChem; 2014 Feb; 9(2):323-36. PubMed ID: 24403170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
